Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy

Overview

Journal J Asthma Allergy

Publisher Dove Medical Press

Date 2021 Mar 11

PMID 33692627

Citations 4

Authors

TaoMing Liu

Juan Bai

Su Wang

Shuni Ying

Sheng Li

Jianjun Qiao

Hong Fang

Affiliations

Soon will be listed here.

Abstract

Prurigo nodularis (PN) is an intense pruritic skin condition. Treatment of PN is challenging. We described an elderly patient with PN who had contradictions of cyclosporine or methotrexate and achieved significant improvement after treatment with dupilumab. We also reviewed published cases of elderly patients with PN who were refractory to traditional therapy.

Citing Articles

Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

Olbrich H, Sadik C, Ludwig R, Thaci D, Boch K Biomolecules. 2023; 13(4).

PMID: 37189381 PMC: 10136243. DOI: 10.3390/biom13040634.

Dupilumab for the treatment of prurigo nodularis: A systematic review.

Cao P, Xu W, Jiang S, Zhang L Front Immunol. 2023; 14:1092685.

PMID: 36742321 PMC: 9895771. DOI: 10.3389/fimmu.2023.1092685.

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis.

Mitsuyama S, Higuchi T An Bras Dermatol. 2022; 98(1):86-89.

PMID: 36376117 PMC: 9837645. DOI: 10.1016/j.abd.2022.01.011.

Immunotargets and Therapy for Prurigo Nodularis.

Labib A, Ju T, Does A, Yosipovitch G Immunotargets Ther. 2022; 11:11-21.

PMID: 35502157 PMC: 9056055. DOI: 10.2147/ITT.S316602.

References

Williams K, Huang A, Belzberg M, Kwatra S . Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol. 2020; 83(6):1567-1575. DOI: 10.1016/j.jaad.2020.04.182. View

Criado P, Pincelli T, Criado R . Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. Int J Dermatol. 2020; 59(10):e358-e361. DOI: 10.1111/ijd.14994. View

Park K, Mori T, Nakamura M, Tokura Y . Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur J Dermatol. 2011; 21(1):135-6. DOI: 10.1684/ejd.2010.1196. View

Wieser J, Mercurio M, Somers K . Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series. Cureus. 2020; 12(6):e8737. PMC: 7377018. DOI: 10.7759/cureus.8737. View

Zhong W, Wu X, Zhang W, Zhang J, Chen X, Chen S . Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. Acta Derm Venereol. 2019; 99(6):579-586. DOI: 10.2340/00015555-3150. View

Huang A, Canner J, Kang S, Kwatra S . Analysis of real-world treatment patterns in patients with prurigo nodularis. J Am Acad Dermatol. 2019; 82(1):34-36. DOI: 10.1016/j.jaad.2019.09.007. View

Beck L, Thaci D, Hamilton J, Graham N, Bieber T, Rocklin R . Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014; 371(2):130-9. DOI: 10.1056/NEJMoa1314768. View

Kovacs B, Rose E, Kuznik N, Shimanovich I, Zillikens D, Ludwig R . Dupilumab for treatment-refractory prurigo nodularis. J Dtsch Dermatol Ges. 2020; 18(6):618-624. DOI: 10.1111/ddg.14107. View

Giura M, Viola R, Fierro M, Ribero S, Ortoncelli M . Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2019; 33(1):e13201. DOI: 10.1111/dth.13201. View

10.

Beck K, Yang E, Sekhon S, Bhutani T, Liao W . Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2018; 155(1):118-120. DOI: 10.1001/jamadermatol.2018.3912. View

11.

Stander S, Yosipovitch G, Legat F, Lacour J, Paul C, Narbutt J . Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020; 382(8):706-716. DOI: 10.1056/NEJMoa1908316. View